LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 26

Search options

  1. Article ; Online: Longitudinal Changes in Sex Hormone Binding Globulin (SHBG) and Risk of Incident Diabetes: The Study of Women's Health Across the Nation (SWAN).

    Hedderson, Monique M / Capra, Angela / Lee, Catherine / Habel, Laurel A / Lee, Jennifer / Gold, Ellen B / Badon, Sylvia E / Mitro, Susanna D / El Khoudary, Samar R

    Diabetes care

    2024  Volume 47, Issue 4, Page(s) 676–682

    Abstract: Objective: To investigate the associations of longitudinal changes in sex hormone binding globulin (SHBG) and testosterone (T) over the menopause transition with the risk of diabetes.: Research design and methods: We followed 2,952 participants in ... ...

    Abstract Objective: To investigate the associations of longitudinal changes in sex hormone binding globulin (SHBG) and testosterone (T) over the menopause transition with the risk of diabetes.
    Research design and methods: We followed 2,952 participants in the Study of Women's Health Across the Nation (SWAN) who were premenopausal or early perimenopausal and diabetes-free at baseline. SHBG,T, and estradiol (E2) levels were measured at up to 13 follow-up visits (over up to 17 years). We used complementary log-log-based discrete-time survival models anchored at baseline.
    Results: Diabetes developed in 376 women. A 5-unit increase in time-varying SHBG was associated with a 10% reduced risk of diabetes (hazard ratio [HR] 0.91, 95% CI 0.87-0.95), adjusting for covariates, and baseline SHBG,T, and E2 levels. Time-varying T was not associated with diabetes risk. Compared with the lowest quartile for annual rate of change of SHBG since baseline (quartile 1 [Q1] -92.3 to -1.5 nmol/L), all other quartiles were associated with a decreased risk of diabetes adjusting for covariates and baseline SHBG; associations persisted after adjusting for rate of change of T and E2 (Q2 [> -1.5 to -0.2 nmol/L] HR 0.33, 95% CI 0.23-0.48; Q3 [> -0.2 to 1.3 nmol/L] HR 0.37, 95% CI 0.25-0.55; Q4 [>1.3 to 82.0 nmol/L] HR 0.43, 95% CI 0.30-0.63).
    Conclusions: Increasing levels of SHBG over the menopause transition were associated with a decreased risk of incident diabetes. Stable to increasing rates of change in SHBG were also independently associated with a decreased risk of diabetes compared with decreasing rates of change, suggesting SHBG may affect glucose through a mechanism beyond androgenicity.
    MeSH term(s) Female ; Humans ; Diabetes Mellitus/epidemiology ; Estradiol ; Menopause ; Sex Hormone-Binding Globulin/metabolism ; Testosterone ; Women's Health
    Chemical Substances Estradiol (4TI98Z838E) ; Sex Hormone-Binding Globulin ; Testosterone (3XMK78S47O) ; SHBG protein, human
    Language English
    Publishing date 2024-02-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 441231-x
    ISSN 1935-5548 ; 0149-5992
    ISSN (online) 1935-5548
    ISSN 0149-5992
    DOI 10.2337/dc23-1630
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments.

    Zhang, Eva / Nguyen, Thi H O / Allen, Lilith F / Kedzierski, Lukasz / Rowntree, Louise C / Chang, So Young / Zhang, Wuji / Habel, Jennifer R / Foo, Isabelle J / Menon, Tejas / Mitchell, Jeni / Leong, Rupert W / Bond, Katherine / Williamson, Deborah A / Kedzierska, Katherine / Christensen, Britt

    Gut

    2024  Volume 73, Issue 4, Page(s) 712–714

    MeSH term(s) Humans ; COVID-19 Vaccines ; COVID-19/prevention & control ; SARS-CoV-2 ; T-Lymphocytes ; Tumor Necrosis Factor Inhibitors ; Antibodies, Viral ; Inflammatory Bowel Diseases/drug therapy ; Vaccination
    Chemical Substances COVID-19 Vaccines ; Tumor Necrosis Factor Inhibitors ; Antibodies, Viral
    Language English
    Publishing date 2024-03-07
    Publishing country England
    Document type Letter
    ZDB-ID 80128-8
    ISSN 1468-3288 ; 0017-5749
    ISSN (online) 1468-3288
    ISSN 0017-5749
    DOI 10.1136/gutjnl-2022-329136
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Immunohistopathology of oral mucosal chronic graft-versus-host disease severity and duration.

    Tollemar, Victor / Ström, Jennifer / Tudzarovski, Nikolce / Häbel, Henrike / Legert, Karin Garming / Heymann, Robert / Warfvinge, Gunnar / Le Blanc, Katarina / Sugars, Rachael Victoria

    Oral diseases

    2022  Volume 29, Issue 8, Page(s) 3346–3359

    Abstract: Objective: Chronic graft-versus-host disease (cGVHD) is the main cause of late non-relapse mortality following hematopoietic cell transplantation. Oral mucosal (om-) cGVHD is common, but diagnosis and assessment rely on clinical interpretation and ... ...

    Abstract Objective: Chronic graft-versus-host disease (cGVHD) is the main cause of late non-relapse mortality following hematopoietic cell transplantation. Oral mucosal (om-) cGVHD is common, but diagnosis and assessment rely on clinical interpretation and patient-reported symptoms. We investigated immunohistopathological profiles with respect to om-cGVHD severity disease duration.
    Material and methods: Ninety-four transplant patients and 15 healthy controls (n = 212 biopsies) were investigated by quantitative immunohistochemistry for T cells (CD4, CD8, and CD5), B cells (CD19 and CD20), macrophages (CD68), and Langerhans cells (CD1a).
    Results: We found significant increases in T (CD4, CD8) and monocytic (CD68) cells in om-cGVHD, and a notable absence of B (CD19 and CD20) cells. Histopathological activity correlated with increased CD4, CD8 and CD68. However, CD4 was associated with mild om-cGVHD, whereas CD8 and CD68 were found to be elevated in severe om-cGVHD. CD8 and CD68 levels were raised at disease onset, but during late phase, the predominant CD68 population was accompanied by CD4.
    Conclusion: Oral cGVHD is a heterogenous clinical disorder, but our knowledge of the underlying biology remains limited. We highlight the importance of CD4, CD8 and CD68 immune profiling, together with histological grading for the staging of oral cGVHD, to broaden our understanding of the biology and individual disease course.
    MeSH term(s) Humans ; Bronchiolitis Obliterans Syndrome ; Graft vs Host Disease ; T-Lymphocytes ; Hematopoietic Stem Cell Transplantation/adverse effects ; Mouth Mucosa/pathology ; Chronic Disease
    Language English
    Publishing date 2022-07-21
    Publishing country Denmark
    Document type Journal Article
    ZDB-ID 1290529-x
    ISSN 1601-0825 ; 1354-523X
    ISSN (online) 1601-0825
    ISSN 1354-523X
    DOI 10.1111/odi.14303
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Are NKT cells a useful predictor of COVID-19 severity?

    Koay, Hui-Fern / Gherardin, Nicholas A / Nguyen, Thi H O / Zhang, Wuji / Habel, Jennifer R / Seneviratna, Rebecca / James, Fiona / Holmes, Natasha E / Smibert, Olivia C / Gordon, Claire L / Trubiano, Jason A / Kedzierska, Katherine / Godfrey, Dale I

    Immunity

    2022  Volume 55, Issue 2, Page(s) 185–187

    MeSH term(s) COVID-19 ; Cytokines ; Flow Cytometry ; Humans ; Natural Killer T-Cells ; SARS-CoV-2
    Chemical Substances Cytokines
    Language English
    Publishing date 2022-01-19
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1217235-2
    ISSN 1097-4180 ; 1074-7613
    ISSN (online) 1097-4180
    ISSN 1074-7613
    DOI 10.1016/j.immuni.2022.01.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: T Cell Epitope Discovery in the Context of Distinct and Unique Indigenous HLA Profiles.

    Hensen, Luca / Illing, Patricia T / Rowntree, Louise C / Davies, Jane / Miller, Adrian / Tong, Steven Y C / Habel, Jennifer R / van de Sandt, Carolien E / Flanagan, Katie L / Purcell, Anthony W / Kedzierska, Katherine / Clemens, E Bridie

    Frontiers in immunology

    2022  Volume 13, Page(s) 812393

    Abstract: ... ...

    Abstract CD8
    MeSH term(s) Australia ; CD8-Positive T-Lymphocytes ; Chromatography, Liquid ; Epitopes, T-Lymphocyte ; HLA Antigens ; Histocompatibility Antigens Class I ; Histocompatibility Antigens Class II ; Humans ; Influenza Vaccines ; Influenza, Human ; Tandem Mass Spectrometry
    Chemical Substances Epitopes, T-Lymphocyte ; HLA Antigens ; Histocompatibility Antigens Class I ; Histocompatibility Antigens Class II ; Influenza Vaccines
    Language English
    Publishing date 2022-05-06
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2022.812393
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: HLA-A*11:01-restricted CD8+ T cell immunity against influenza A and influenza B viruses in Indigenous and non-Indigenous people.

    Habel, Jennifer R / Nguyen, Andrea T / Rowntree, Louise C / Szeto, Christopher / Mifsud, Nicole A / Clemens, E Bridie / Loh, Liyen / Chen, Weisan / Rockman, Steve / Nelson, Jane / Davies, Jane / Miller, Adrian / Tong, Steven Y C / Rossjohn, Jamie / Gras, Stephanie / Purcell, Anthony W / Hensen, Luca / Kedzierska, Katherine / Illing, Patricia T

    PLoS pathogens

    2022  Volume 18, Issue 3, Page(s) e1010337

    Abstract: HLA-A*11:01 is one of the most prevalent human leukocyte antigens (HLAs), especially in East Asian and Oceanian populations. It is also highly expressed in Indigenous people who are at high risk of severe influenza disease. As CD8+ T cells can provide ... ...

    Abstract HLA-A*11:01 is one of the most prevalent human leukocyte antigens (HLAs), especially in East Asian and Oceanian populations. It is also highly expressed in Indigenous people who are at high risk of severe influenza disease. As CD8+ T cells can provide broadly cross-reactive immunity to distinct influenza strains and subtypes, including influenza A, B and C viruses, understanding CD8+ T cell immunity to influenza viruses across prominent HLA types is needed to rationally design a universal influenza vaccine and generate protective immunity especially for high-risk populations. As only a handful of HLA-A*11:01-restricted CD8+ T cell epitopes have been described for influenza A viruses (IAVs) and epitopes for influenza B viruses (IBVs) were still unknown, we embarked on an epitope discovery study to define a CD8+ T cell landscape for HLA-A*11:01-expressing Indigenous and non-Indigenous Australian people. Using mass-spectrometry, we identified IAV- and IBV-derived peptides presented by HLA-A*11:01 during infection. 79 IAV and 57 IBV peptides were subsequently screened for immunogenicity in vitro with peripheral blood mononuclear cells from HLA-A*11:01-expressing Indigenous and non-Indigenous Australian donors. CD8+ T cell immunogenicity screening revealed two immunogenic IAV epitopes (A11/PB2320-331 and A11/PB2323-331) and the first HLA-A*11:01-restricted IBV epitopes (A11/M41-49, A11/NS1186-195 and A11/NP511-520). The immunogenic IAV- and IBV-derived peptides were >90% conserved among their respective influenza viruses. Identification of novel immunogenic HLA-A*11:01-restricted CD8+ T cell epitopes has implications for understanding how CD8+ T cell immunity is generated towards IAVs and IBVs. These findings can inform the development of rationally designed, broadly cross-reactive influenza vaccines to ensure protection from severe influenza disease in HLA-A*11:01-expressing individuals.
    MeSH term(s) Australia ; CD8-Positive T-Lymphocytes ; Epitopes, T-Lymphocyte ; HLA-A Antigens ; Humans ; Indigenous Peoples ; Influenza A virus ; Influenza B virus ; Influenza Vaccines ; Influenza, Human ; Leukocytes, Mononuclear ; Peptides
    Chemical Substances Epitopes, T-Lymphocyte ; HLA-A Antigens ; Influenza Vaccines ; Peptides
    Language English
    Publishing date 2022-03-07
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2205412-1
    ISSN 1553-7374 ; 1553-7374
    ISSN (online) 1553-7374
    ISSN 1553-7374
    DOI 10.1371/journal.ppat.1010337
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Immunization with inactivated whole virus particle influenza virus vaccines improves the humoral response landscape in cynomolgus macaques.

    Chua, Brendon Y / Sekiya, Toshiki / Koutsakos, Marios / Nomura, Naoki / Rowntree, Louise C / Nguyen, Thi H O / McQuilten, Hayley A / Ohno, Marumi / Ohara, Yuki / Nishimura, Tomohiro / Endo, Masafumi / Itoh, Yasushi / Habel, Jennifer R / Selva, Kevin J / Wheatley, Adam K / Wines, Bruce D / Hogarth, P Mark / Kent, Stephen J / Chung, Amy W /
    Jackson, David C / Brown, Lorena E / Shingai, Masashi / Kedzierska, Katherine / Kida, Hiroshi

    PLoS pathogens

    2022  Volume 18, Issue 10, Page(s) e1010891

    Abstract: Although antibody-inducing split virus vaccines (SV) are currently the most effective way to combat seasonal influenza, their efficacy can be modest, especially in immunologically-naïve individuals. We investigated immune responses towards inactivated ... ...

    Abstract Although antibody-inducing split virus vaccines (SV) are currently the most effective way to combat seasonal influenza, their efficacy can be modest, especially in immunologically-naïve individuals. We investigated immune responses towards inactivated whole influenza virus particle vaccine (WPV) formulations, predicated to be more immunogenic, in a non-human primate model, as an important step towards clinical testing in humans. Comprehensive analyses were used to capture 46 immune parameters to profile how WPV-induced responses differed to those elicited by antigenically-similar SV formulations. Naïve cynomolgus macaques vaccinated with either monovalent or quadrivalent WPV consistently induced stronger antibody responses and hemagglutination inhibition (HI) antibody titres against vaccine-matched viruses compared to SV formulations, while acute reactogenic effects were similar. Responses in WPV-primed animals were further increased by boosting with the same formulation, conversely to modest responses after priming and boosting with SV. 28-parameter multiplex bead array defined key antibody features and showed that while both WPV and SV induced elevated IgG responses against A/H1N1 nucleoprotein, only WPV increased IgG responses against A/H1N1 hemagglutinin (HA) and HA-Stem, and higher IgA responses to A/H1N1-HA after each vaccine dose. Antibodies to A/H1N1-HA and HA-Stem that could engage FcγR2a and FcγR3a were also present at higher levels after one dose of WPV compared to SV and remained elevated after the second dose. Furthermore, WPV-enhanced antibody responses were associated with higher frequencies of HA-specific B-cells and IFN-γ-producing CD4+ T-cell responses. Our data additionally demonstrate stronger boosting of HI titres by WPV following prior infection and support WPV administered as a priming dose irrespective of the follow up vaccine for the second dose. Our findings thus show that compared to SV vaccination, WPV-induced humoral responses are significantly increased in scope and magnitude, advocating WPV vaccination regimens for priming immunologically-naïve individuals and also in the event of a pandemic outbreak.
    MeSH term(s) Animals ; Humans ; Influenza Vaccines ; Influenza A Virus, H1N1 Subtype ; Hemagglutinins ; Antibodies, Viral ; Vaccination ; Influenza, Human ; Hemagglutination Inhibition Tests ; Vaccines, Inactivated ; Macaca fascicularis ; Virion ; Immunoglobulin A ; Immunoglobulin G ; Nucleoproteins
    Chemical Substances Influenza Vaccines ; Hemagglutinins ; Antibodies, Viral ; Vaccines, Inactivated ; Immunoglobulin A ; Immunoglobulin G ; Nucleoproteins
    Language English
    Publishing date 2022-10-07
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2205412-1
    ISSN 1553-7374 ; 1553-7374
    ISSN (online) 1553-7374
    ISSN 1553-7374
    DOI 10.1371/journal.ppat.1010891
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Immune profiling of SARS-CoV-2 infection during pregnancy reveals NK cell and γδ T cell perturbations.

    Habel, Jennifer R / Chua, Brendon Y / Kedzierski, Lukasz / Selva, Kevin J / Damelang, Timon / Haycroft, Ebene R / Nguyen, Thi Ho / Koay, Hui-Fern / Nicholson, Suellen / McQuilten, Hayley A / Jia, Xiaoxiao / Allen, Lilith F / Hensen, Luca / Zhang, Wuji / van de Sandt, Carolien E / Neil, Jessica A / Pragastis, Katherine / Lau, Jillian Sy / Jumarang, Jaycee /
    Allen, E Kaitlynn / Amanant, Fatima / Krammer, Florian / Wragg, Kathleen M / Juno, Jennifer A / Wheatley, Adam K / Tan, Hyon-Xhi / Pell, Gabrielle / Walker, Susan / Audsley, Jennifer / Reynaldi, Arnold / Thevarajan, Irani / Denholm, Justin T / Subbarao, Kanta / Davenport, Miles P / Hogarth, P Mark / Godfrey, Dale I / Cheng, Allen C / Tong, Steven Yc / Bond, Katherine / Williamson, Deborah A / McMahon, James H / Thomas, Paul G / Pannaraj, Pia S / James, Fiona / Holmes, Natasha E / Smibert, Olivia C / Trubiano, Jason A / Gordon, Claire L / Chung, Amy W / Whitehead, Clare L / Kent, Stephen J / Lappas, Martha / Rowntree, Louise C / Kedzierska, Katherine

    JCI insight

    2023  Volume 8, Issue 7

    Abstract: Pregnancy poses a greater risk for severe COVID-19; however, underlying immunological changes associated with SARS-CoV-2 during pregnancy are poorly understood. We defined immune responses to SARS-CoV-2 in unvaccinated pregnant and nonpregnant women with ...

    Abstract Pregnancy poses a greater risk for severe COVID-19; however, underlying immunological changes associated with SARS-CoV-2 during pregnancy are poorly understood. We defined immune responses to SARS-CoV-2 in unvaccinated pregnant and nonpregnant women with acute and convalescent COVID-19, quantifying 217 immunological parameters. Humoral responses to SARS-CoV-2 were similar in pregnant and nonpregnant women, although our systems serology approach revealed distinct antibody and FcγR profiles between pregnant and nonpregnant women. Cellular analyses demonstrated marked differences in NK cell and unconventional T cell activation dynamics in pregnant women. Healthy pregnant women displayed preactivated NK cells and γδ T cells when compared with healthy nonpregnant women, which remained unchanged during acute and convalescent COVID-19. Conversely, nonpregnant women had prototypical activation of NK and γδ T cells. Activation of CD4+ and CD8+ T cells and T follicular helper cells was similar in SARS-CoV-2-infected pregnant and nonpregnant women, while antibody-secreting B cells were increased in pregnant women during acute COVID-19. Elevated levels of IL-8, IL-10, and IL-18 were found in pregnant women in their healthy state, and these cytokine levels remained elevated during acute and convalescent COVID-19. Collectively, we demonstrate perturbations in NK cell and γδ T cell activation in unvaccinated pregnant women with COVID-19, which may impact disease progression and severity during pregnancy.
    MeSH term(s) Pregnancy ; Female ; Humans ; COVID-19 ; SARS-CoV-2 ; Killer Cells, Natural ; CD8-Positive T-Lymphocytes ; Antibodies
    Chemical Substances Antibodies
    Language English
    Publishing date 2023-04-10
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ISSN 2379-3708
    ISSN (online) 2379-3708
    DOI 10.1172/jci.insight.167157
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments

    Zhang, Eva / Nguyen, Thi O / Allen, Lilith / Kedzierski, Lukasz / Rowntree, Louise C / Chang, So Young / Foo, Isabelle J / Habel, Jennifer R / Zhang, Wuji / Menon, Tejas / Mitchell, Jeni / Leong, Rupert / Bond, Katherine / Williamson, Deborah A / Christensen, Britt / Kedzierska, Katherine

    medRxiv

    Abstract: BACKGROUND AND AIMS: Vaccine-mediated immune responses in patients with inflammatory bowel disease (IBD) may be influenced by IBD therapies. We investigated in-depth humoral and T-cell responses to SARS-CoV-2 vaccination in IBD patients following three ... ...

    Abstract BACKGROUND AND AIMS: Vaccine-mediated immune responses in patients with inflammatory bowel disease (IBD) may be influenced by IBD therapies. We investigated in-depth humoral and T-cell responses to SARS-CoV-2 vaccination in IBD patients following three COVID-19 vaccine doses. METHODS: Immune responses of 100 SARS-CoV-2-uninfected IBD patients on varying treatments were compared to healthy controls (n=35). Anti-S1/2 and anti-RBD SARS-CoV-2-specific antibodies, CD4+ and CD8+ T-cell responses were measured at baseline and at five time-points after COVID-19 vaccination. RESULTS: Anti-S1/2 and anti-RBD antibody concentrations at ~1 month after second dose vaccination were significantly lower in anti-TNF-treated patients compared to non-TNF IBD patients and healthy controls (126.4 vs 262.1 and 295.5, p<0.0001). Anti-S1/2 antibodies remained reduced in anti-TNF treated patients before and after the third dose (285.7 vs 365.3, p=0.03), although anti-RBD antibodies reached comparable titres to non-TNF patients. Anti-RBD antibodies were higher in the vedolizumab group than controls after second dose (4.2 vs 3.6, p=0.003). Anti-TNF monotherapy was associated with increased CD4+ and CD8+ T-cell activation compared to combination anti-TNF patients after second dose, but comparable after third dose. Overall, IBD patients demonstrated similar CD4+/CD8+ T-cell responses compared to healthy controls regardless of treatment regimen. CONCLUSIONS: Anti-TNFs impaired antibody concentrations when compared to non-TNF patients and controls after two vaccine doses. These differences were not observed after the third vaccine dose. However, vaccine induced SARS-CoV-2-specific T cell responses are robust in anti-TNF-treated patients. Our study supports the need for timely booster vaccination particularly in anti-TNF treated patients to minimise the risk of severe SARS-CoV-2 infection.
    Keywords covid19
    Language English
    Publishing date 2022-12-14
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2022.12.13.22283434
    Database COVID19

    Kategorien

  10. Article ; Online: HLA-A*11:01-restricted CD8+ T cell immunity against influenza A and influenza B viruses in Indigenous and non-Indigenous people.

    Jennifer R Habel / Andrea T Nguyen / Louise C Rowntree / Christopher Szeto / Nicole A Mifsud / E Bridie Clemens / Liyen Loh / Weisan Chen / Steve Rockman / Jane Nelson / Jane Davies / Adrian Miller / Steven Y C Tong / Jamie Rossjohn / Stephanie Gras / Anthony W Purcell / Luca Hensen / Katherine Kedzierska / Patricia T Illing

    PLoS Pathogens, Vol 18, Iss 3, p e

    2022  Volume 1010337

    Abstract: HLA-A*11:01 is one of the most prevalent human leukocyte antigens (HLAs), especially in East Asian and Oceanian populations. It is also highly expressed in Indigenous people who are at high risk of severe influenza disease. As CD8+ T cells can provide ... ...

    Abstract HLA-A*11:01 is one of the most prevalent human leukocyte antigens (HLAs), especially in East Asian and Oceanian populations. It is also highly expressed in Indigenous people who are at high risk of severe influenza disease. As CD8+ T cells can provide broadly cross-reactive immunity to distinct influenza strains and subtypes, including influenza A, B and C viruses, understanding CD8+ T cell immunity to influenza viruses across prominent HLA types is needed to rationally design a universal influenza vaccine and generate protective immunity especially for high-risk populations. As only a handful of HLA-A*11:01-restricted CD8+ T cell epitopes have been described for influenza A viruses (IAVs) and epitopes for influenza B viruses (IBVs) were still unknown, we embarked on an epitope discovery study to define a CD8+ T cell landscape for HLA-A*11:01-expressing Indigenous and non-Indigenous Australian people. Using mass-spectrometry, we identified IAV- and IBV-derived peptides presented by HLA-A*11:01 during infection. 79 IAV and 57 IBV peptides were subsequently screened for immunogenicity in vitro with peripheral blood mononuclear cells from HLA-A*11:01-expressing Indigenous and non-Indigenous Australian donors. CD8+ T cell immunogenicity screening revealed two immunogenic IAV epitopes (A11/PB2320-331 and A11/PB2323-331) and the first HLA-A*11:01-restricted IBV epitopes (A11/M41-49, A11/NS1186-195 and A11/NP511-520). The immunogenic IAV- and IBV-derived peptides were >90% conserved among their respective influenza viruses. Identification of novel immunogenic HLA-A*11:01-restricted CD8+ T cell epitopes has implications for understanding how CD8+ T cell immunity is generated towards IAVs and IBVs. These findings can inform the development of rationally designed, broadly cross-reactive influenza vaccines to ensure protection from severe influenza disease in HLA-A*11:01-expressing individuals.
    Keywords Immunologic diseases. Allergy ; RC581-607 ; Biology (General) ; QH301-705.5
    Subject code 570 ; 610
    Language English
    Publishing date 2022-03-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top